Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusion.

Frontiers in oncology·2026
Same author

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.

Nature communications·2026
Same author

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).

The Journal of molecular diagnostics : JMD·2026

Related Experiment Video

Updated: Nov 26, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K

Successful olaparib desensitization using a novel one-day protocol.

Rongbo Zhu1, Stephen Welch2, Hannah Roberts3

  • 1Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON, Canada. Rongbo.Zhu@lhsc.on.ca.

Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|December 9, 2020
PubMed
Summary
This summary is machine-generated.

A novel 1-day desensitization protocol successfully enabled a patient with olaparib hypersensitivity to switch from capsules to tablets. This breakthrough offers hope for managing hypersensitivity reactions to olaparib, a vital cancer treatment.

Keywords:
Chemotherapy agentDrug allergyDrug desensitizationOlaparib

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.5K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

12.9K

Related Experiment Videos

Last Updated: Nov 26, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.5K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

12.9K

Area of Science:

  • Oncology
  • Clinical Immunology
  • Pharmacology

Background:

  • Olaparib is a crucial treatment for ovarian and breast cancers.
  • IgE-mediated hypersensitivity reactions to olaparib are documented.
  • No established 1-day desensitization protocol exists for olaparib hypersensitivity.

Purpose of the Study:

  • To report the first case of successful olaparib desensitization using a novel 1-day protocol.
  • To demonstrate the feasibility of transitioning patients from olaparib capsules to tablets after desensitization.
  • To contribute to the limited data on drug desensitization for chemotherapeutic agents.

Main Methods:

  • A 58-year-old female patient with immediate, IgE-mediated hypersensitivity to olaparib tablets was treated.
  • A novel 1-day desensitization protocol was implemented for olaparib.
  • The patient was transitioned from olaparib capsules to tablets post-desensitization.

Main Results:

  • The 1-day desensitization protocol was successfully implemented.
  • The patient tolerated the transition from olaparib capsules to tablets without loss of tolerance.
  • Immediate, reproducible IgE-mediated adverse reactions to olaparib were managed.

Conclusions:

  • This is the first reported case of successful olaparib desensitization using a 1-day protocol.
  • Drug desensitization is crucial for managing hypersensitivity to chemotherapeutic agents.
  • Transitioning from olaparib capsules to tablets is feasible post-desensitization without compromising tolerance.